APO-TAMOX TAB 10MG 10 MG
TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG · DIN 00812404 · APOTEX INC
Health Canada status: MARKETED
What is APO-TAMOX TAB 10MG?
APO-TAMOX TAB 10MG 10 MG contains TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 00812404, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1989. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-TAMOX TAB 10MG used for?
Adjuvant treatment of early breast cancer (ER+); treatment of hormone responsive locally advanced or metastatic breast cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00812404 |
|---|---|
| Brand name | APO-TAMOX TAB 10MG |
| Generic / active ingredient | TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG |
| Manufacturer | APOTEX INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L02BA01 TAMOXIFEN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1989 |
| Original market date | 1989-12-31 00:00:00 |
How is it administered?
20 to 40 mg daily in single or two divided doses. In early disease, recommended duration is 5 years. Splitting 20 mg tablets is not recommended.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content truncated), though general stability is implied.
How is it supplied?
10 mg: Bottles of 100 and 500. 20 mg: Bottles of 100 and 250.
Contraindications
Hypersensitivity to drug/ingredients; pregnancy; history of stroke, DVT, or pulmonary embolism (when used in prevention setting); increased risk of endometrial cancer.
Warnings and precautions
Serious risks: uterine malignancies, stroke, pulmonary embolism, and DVT. May prolong QTc interval. Risk of hypercalcemia in patients with bone metastases.
What can be used instead?
Other Canadian products sharing ATC code L02BA01 TAMOXIFEN. 4 of 24 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TAMOX TAB 20MG | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 00812390 |
| TEVA-TAMOXIFEN | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00851965 |
| TEVA-TAMOXIFEN | 20 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00851973 |
| DOM-TAMOXIFEN | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02237598 |
| DOM-TAMOXIFEN | 20 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02237599 |
| MYLAN-TAMOXIFEN | 10 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02088428 |
| MYLAN-TAMOXIFEN | 20 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02089858 |
| NOLVADEX TAB 10MG | 10 MG | TABLET | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | DIN 02048477 |
| NOLVADEX-D TAB 20MG | 20 MG | TABLET | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | DIN 02048485 |
| PMS-TAMOXIFEN | 10 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02237459 |
Who else supplies TAMOXIFEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TAMOXIFEN appears in 93 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.